A Study for Patients With Non-Hodgkin's Lymphomas

• Status: Completed
• Trial end date: 2018-02-27
• Target enrollment: 0
• Participant gender: All

Summary

In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma. Each tumor type will include several tumor subtypes:

• T-cell lymphoma: Peripheral and Cutaneous T-cell lymphoma (PTCL, CTCL)

• Indolent B-cell lymphoma: Small lymphocytic lymphoma, follicular lymphoma (Gr 1 or 2) and marginal zone lymphoma

• Aggressive B-cell lymphoma: Primary CNS lymphoma, follicular lymphoma (Gr 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Have measurable lesions

• Have recovered from prior chemotherapies

• Have an estimated life expectancy of at least 12 weeks

• Hepatic: total bilirubin less than or equal to 1.5 XULN; ATL/AST less than or equal to 2.0 x ULN (less than 5x if liver metastases are present)

• Renal: serum creatinine less than or equal to 1.5XULN

• Adequate bone marrow reserve: platelets greater than or equal to 75 x 109 /Liter (L) Criteria:

• Have a second primary malignancy (except adequately treated nonmelanomatous skin cancer, or other cancer that is considered cured by surgical resection or radiation).

• Anti-lymphoma therapy within the past 3 weeks

• Unable to swallow tablets

• Unable to discontinue use of carbamazepine, phenobarbital and phenytoin at least 14 days prior to study enrollment